| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Akouos Inc (NASDAQ: AKUS)
AKUS Technical Analysis
4
| As on 1st Dec 2022 AKUS SHARE Price closed @ 13.29 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 8.42 & Buy for SHORT-TERM with Stoploss of 12.05 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AKUSSHARE Price
| Open | 13.29 | Change | Price | % |
| High | 13.29 | 1 Day | 0.00 | 0.00 |
| Low | 13.29 | 1 Week | 0.06 | 0.45 |
| Close | 13.29 | 1 Month | 0.04 | 0.30 |
| Volume | N/A | 1 Year | 0.14 | 1.06 |
| 52 Week High 15.07 | 52 Week Low 2.46 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| LCID | 2.16 | 5.37% |
| HCTI | 0.03 | 50.00% |
| NVDA | 159.34 | 1.33% |
| LMDX | 0.02 | 0.00% |
| AKTS | 0.04 | 0.00% |
| PLUG | 1.47 | 5.00% |
| WINT | 0.93 | 20.78% |
| BTBT | 2.94 | 11.79% |
| LILM | 0.05 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AKUS Daily Charts |
AKUS Intraday Charts |
Whats New @ Bazaartrend |
AKUS Free Analysis |
|
|
AKUS Important Levels Intraday
| RESISTANCE | 13.29 |
| RESISTANCE | 13.29 |
| RESISTANCE | 13.29 |
| RESISTANCE | 13.29 |
| RESISTANCE | 13.29 |
| RESISTANCE | 13.29 |
| RESISTANCE | 13.29 |
| RESISTANCE | 13.29 |
AKUS Forecast July 2025
| 4th UP Forecast | 22.04 |
| 3rd UP Forecast | 19.23 |
| 2nd UP Forecast | 17.5 |
| 1st UP Forecast | 15.76 |
| 1st DOWN Forecast | 10.82 |
| 2nd DOWN Forecast | 9.08 |
| 3rd DOWN Forecast | 7.35 |
| 4th DOWN Forecast | 4.54 |
AKUS Weekly Forecast
| 4th UP Forecast | 19.21 |
| 3rd UP Forecast | 17.31 |
| 2nd UP Forecast | 16.14 |
| 1st UP Forecast | 14.96 |
| 1st DOWN Forecast | 11.62 |
| 2nd DOWN Forecast | 10.44 |
| 3rd DOWN Forecast | 9.27 |
| 4th DOWN Forecast | 7.37 |
AKUS Forecast2025
| 4th UP Forecast | 38.24 |
| 3rd UP Forecast | 30.24 |
| 2nd UP Forecast | 25.29 |
| 1st UP Forecast | 20.35 |
| 1st DOWN Forecast | 6.23 |
| 2nd DOWN Forecast | 1.29 |
| 3rd DOWN Forecast | -3.66 |
| 4th DOWN Forecast | -11.66 |
Akouos Inc ( NASDAQ USA Symbol : AKUS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AKUS Business Profile
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts. Address: 645 Summer Street, Boston, MA, United States, 02210
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service